Terbinafine Tablets (Terbinafine Hydrochloride)

Adult dosage

Administer 125 mg of terbinafine per dose, twice a day, or 250 mg per dose, once a day. The duration of treatment varies with the disease as follows: 1) Dermatophytosis Athlete's foot (interdigital type, plantar type/moccasin type): 2 to 6 weeks Tinea corporis: 2 to 4 weeks Tinea cruris: 2 to 4 weeks 2) Onychomycosis Typically treated for 6 weeks to 3 months. If the infection is in the fingernails or smaller toes, or if the patient is a younger child, the treatment period may be shortened to less than 3 months. The treatment period for toenail infections is usually sufficient at 3 months, but in some patients, it may take 6 months or longer. In patients with slow nail growth, the treatment period may be extended.

Children's dosage

Administer to children over 2 years old. There is no experience with administration in children under 2 years old, so it is not recommended. Tinea capitis: 4 weeks 1) Weight under 20 kg (under 5 years old): 1 dose of 62.5 mg, 1

This medication is not recommended for patients with chronic liver disease or active liver disease. Liver function tests must be conducted before administration and periodically during treatment. If symptoms of liver dysfunction appear, discontinue the medication immediately and consult a physician. This medicine should not be administered to patients with blood disorders, severe renal failure, infants under 2 years old, or nursing mothers. Patients with certain genetic disorders should also avoid this medication. Exercise caution when using in patients with decreased kidney function, elderly individuals, or underweight children. If a severe rash or allergic reaction occurs, discontinue the medication immediately. This medicine can cause adverse reactions in various regions, including the liver, blood, skin, muscles, gastrointestinal tract, mental, and nervous systems, so consult medical personnel immediately if any unusual symptoms appear. Caution should be exercised while driving or operating machinery if dizziness occurs. There may be interactions with other medications, so be sure to inform your doctor or pharmacist of any other medications being taken. Women who are pregnant or may become pregnant should carefully consider the risks and benefits of taking this medication, and nursing mothers should cease breastfeeding while taking it. Special care should be taken when administering to children and the elderly, and in cases of overdose, immediate medical attention should be sought. Store this medication out of reach of children and keep it at room temperature, avoiding direct sunlight.

Serious side effects

• Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor
• Hepatobiliary failure, hepatitis, cholestasis, jaundice
• Stevens-Johnson syndrome, toxic epidermal necrolysis
• Rhabdomyolysis with rapid decline of kidney function
• Hypotension, respiratory distress, chest tightness (shock symptoms)
• Anaphylactic reactions (including angioedema and diffuse erythema)
• Paresis
• Severe skin adverse reactions (severe rash, blisters, skin peeling with high fever)

Mild side effects

• Rash, itching, photosensitivity reactions, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriasiform rash, worsening of psoriasis, hair loss
• Musculoskeletal reactions (arthralgia, myalgia), myalgia, weakness, increased CPK, elevated myoglobin in blood and urine
• Hypotension, respiratory distress, chest tightness
• Hives, erythema, facial swelling, lymphangiectasia
• Gastrointestinal symptoms (abdominal distension, decreased appetite, dyspepsia, nausea)

This medicine should be stored in a tightly sealed container to prevent air or moisture from entering. It is best stored at room temperature between 1°C and 30°C.

Appearance

Round tablets, white to off-white in color

Package unit

For oral use - 30 tablets/bottle, For oral use - 100 tablets/bottle